Clinical trialNCT04121221CompletedPhase 3Interventional

A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS

SponsorMapi Pharma Ltd.Enrollment1,016Multiple Sclerosis, Relapsing-Remitting

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing Forms of Multiple Sclerosis (RMS) to assess the efficacy, safety and tolerability of GA Depot, a long acting IM injection of glatiramer acetate, administered once every four weeks

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Aaron E. Miller, Prof. MD
Mount Sinai School of Medicine, New York, US
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Laura Popper, MD
Mapi Pharma Ltd.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

112 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Belarus

Mapi Pharma Research Site 02
Homyel, Belarus
Mapi Pharma Research Site 04
Minsk, Belarus
Mapi Pharma Research Site 05
Minsk, Belarus
Mapi Pharma Research Site 06
Minsk, Belarus
Mapi Pharma Research Site 01
Vitebsk, Belarus
Mapi Pharma Research Site 07
Vitebsk, Belarus

Bosnia and Herzegovina

Mapi Pharma Research Site 04
Banja Luka, Bosnia and Herzegovina
Mapi Pharma Research Site 06
Bihać, Bosnia and Herzegovina
Mapi Pharma Research Site 01
Sarajevo, Bosnia and Herzegovina
Mapi Pharma Research Site 03
Tuzla, Bosnia and Herzegovina

Bulgaria

Mapi Pharma Research Site 14
Haskovo, Bulgaria
Mapi Pharma Research Site 10
Pazardzhik, Bulgaria
Mapi Pharma Research Site 01
Pleven, Bulgaria
Mapi Pharma Research Site 02
Pleven, Bulgaria
Mapi Pharma Research Site 03
Pleven, Bulgaria
Mapi Pharma Research Site 07
Pleven, Bulgaria
Mapi Pharma Research Site 12
Plovdiv, Bulgaria
Mapi Pharma Research Site 18
Rousse, Bulgaria
Mapi Pharma Research Site 04
Sofia, Bulgaria
Mapi Pharma Research Site 05
Sofia, Bulgaria
Mapi Pharma Research Site 06
Sofia, Bulgaria
Mapi Pharma Research Site 08
Sofia, Bulgaria
Mapi Pharma Research Site 11
Sofia, Bulgaria
Mapi Pharma Research Site 13
Sofia, Bulgaria
Mapi Pharma Research Site 15
Sofia, Bulgaria
Mapi Pharma Research Site 16
Sofia, Bulgaria
Mapi Pharma Research Site 19
Sofia, Bulgaria
Mapi Pharma Research Site 09
Veliko Tarnovo, Bulgaria
Mapi Pharma Research Site 17
Vratsa, Bulgaria

Estonia

Mapi Pharma Research Site 01
Tallinn, Estonia

Georgia

Mapi Pharma Research Site 01
Tbilisi, Georgia
Mapi Pharma Research Site 02
Tbilisi, Georgia
Mapi Pharma Research Site 03
Tbilisi, Georgia
Mapi Pharma Research Site 04
Tbilisi, Georgia
Mapi Pharma Research Site 05
Tbilisi, Georgia
Mapi Pharma Research Site 06
Tbilisi, Georgia
Mapi Pharma Research Site 07
Tbilisi, Georgia
Mapi Pharma Research Site 08
Tbilisi, Georgia
Mapi Pharma Research Site 09
Tbilisi, Georgia

Israel

Mapi Pharma Research Site 01
Safed, Israel

72 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

GA Depot

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 19 Sept 2019
Primary completion: 13 Jun 2023
Completion: 13 Jun 2023
Last update posted: 5 Aug 2026
Registered enrollment: 1,016
Registry id: NCT04121221

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.